Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
1.
Z Rheumatol ; 82(6): 491-507, 2023 Aug.
Artigo em Alemão | MEDLINE | ID: mdl-37310467

RESUMO

The ultrasound examination of peripheral nerves has been further developed in recent years and is recognized as an independent discipline by the German Society of Ultrasound in Medicine (DEGUM). A systematic ultrasound examination of the musculoskeletal system is not limited to the joints, muscles and bones but should also include the examination of nerves and blood vessels. Therefore, in the practice of ultrasound examination every rheumatologist should have at least a basic knowledge of the ultrasound examination of the peripheral nerves. In this article the authors present a landmark-based concept in which the three large nerves of the upper extremities can be completely visualized from proximal to distal and evaluated.


Assuntos
Osso e Ossos , Extremidade Superior , Humanos , Extremidade Superior/diagnóstico por imagem , Extremidade Superior/inervação
2.
Z Rheumatol ; 80(1): 29-42, 2021 Feb.
Artigo em Alemão | MEDLINE | ID: mdl-33259008

RESUMO

Osteogenesis imperfecta (brittle bone disease) is an orphan disease caused by a genetic mutation in collagen metabolism. Bone fractures are the most common symptoms; however, the clinical manifestation can vary widely. Additional features can include blue sclera, dwarfism, bone deformities, muscular weakness, scoliosis, hearing loss and hypermobility of joints. Most patients show a reduction of skeletal function. This leads to an increased risk of being unable to continue their former work and to participate in social life. A comprehensive treatment includes drug therapy, surgery and rehabilitation. This article gives an overview of the current status of rehabilitation in adult patients with osteogenesis imperfecta.


Assuntos
Osteogênese Imperfeita , Escoliose , Adulto , Fraturas Ósseas , Humanos , Mutação , Osteogênese Imperfeita/genética , Doenças Raras
3.
Z Rheumatol ; 77(8): 703-718, 2018 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-30097703

RESUMO

Osteomalacia is a bone disease caused by impaired skeletal mineralization. Vitamin D dependent types have to be distinguished from hypophosphatemic forms. Typical signs and symptoms include diffuse bone pain, muscle weakness and fragility fractures. The fracture pattern in osteomalacia is typically different from that of osteoporosis. Fragility fractures of the pelvis, sacrum, distal parts of the foot, proximal tibia and ribs are indicators for osteomalacia, whereas femoral neck and vertebral fractures (wedged vertebra, fish vertebra, vertebra plana and cover plate impression fractures) are typical for osteoporosis. Unspecific clinical features may be the reason for a delayed diagnosis. The correct classification of the complaint is dependent on the knowledge of the pathophysiology of osteomalacia and performance of additional bone-specific examinations. Determination of specific laboratory parameters should follow a rational algorithm, supplemented by imaging methods and a bone biopsy.


Assuntos
Hipofosfatemia , Osteomalacia , Osteoporose , Osso e Ossos , Humanos , Osteomalacia/diagnóstico , Osteomalacia/tratamento farmacológico , Osteoporose/diagnóstico , Vitamina D
4.
Z Rheumatol ; 76(3): 274-278, 2017 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-28084543

RESUMO

Pregnancy and lactation-associated osteoporosis (PLO) is a rare form of osteoporosis, which occurs in the last trimester or postpartum. So far 100 cases have been published. The leading symptoms are severe low back pain or less frequently hip pain. Many patients develop postpartum depression due to inability to care for the baby and vertebral fractures. The therapeutic decision has to be made individually but teriparatid and bisphosphonates seem to be the best option. We report the clinical course (16 years) of a 37-year-old patient with PLO, who suffered 6 vertebral fractures. There were severe physical limitations and mental problems caused by the disease. The patient was treated by multimodal therapy including physiotherapy and psychotherapy and bisphosphonates were given. The time between the onset of symptoms and diagnosis was 5 months. No further fractures occurred in the following 16 years. The physical and mental condition significantly improved.


Assuntos
Depressão/terapia , Transtornos da Lactação/terapia , Fraturas por Osteoporose/terapia , Complicações na Gravidez/terapia , Fraturas da Coluna Vertebral/terapia , Adulto , Conservadores da Densidade Óssea/uso terapêutico , Terapia Combinada/métodos , Depressão/diagnóstico , Diagnóstico Diferencial , Difosfonatos/administração & dosagem , Feminino , Humanos , Transtornos da Lactação/diagnóstico , Traumatismo Múltiplo/diagnóstico , Traumatismo Múltiplo/terapia , Osteoporose , Fraturas por Osteoporose/diagnóstico , Modalidades de Fisioterapia , Gravidez , Complicações na Gravidez/diagnóstico , Psicoterapia/métodos , Fraturas da Coluna Vertebral/diagnóstico , Resultado do Tratamento
5.
Z Rheumatol ; 75(7): 729-35, 2016 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-27193336

RESUMO

Systemic mastocytosis is defined as a clonal increase of mast cells. We report on four patients with severe osteoporosis and histologically confirmed systemic mastocytosis. In spite of antiresorptive therapy the patients developed further vertebral fractures and suffered from ostealgia. Systemic mastocytosis is an important differential diagnosis in patients with therapy refractive and unexplained osteoporosis. Skin involvement (urticaria pigmentosa) is a rare occurrence and in most cases an isolated involvement of bone marrow is present. Determination of serum tryptase can provide indications for systemic mastocytosis but the diagnosis is only confirmed by bone marrow biopsy. There is a high risk of vertebral fractures and patients should be treated in specialized centers. Zoledronic acid can be a therapeutic option for indolent osteoporosis associated with systemic mastocytosis.


Assuntos
Anti-Inflamatórios/uso terapêutico , Difosfonatos/uso terapêutico , Imidazóis/uso terapêutico , Mastocitose Sistêmica/diagnóstico , Mastocitose Sistêmica/tratamento farmacológico , Osteoporose/diagnóstico , Osteoporose/tratamento farmacológico , Adulto , Conservadores da Densidade Óssea/uso terapêutico , Doença Crônica , Diagnóstico Diferencial , Feminino , Humanos , Masculino , Mastocitose Sistêmica/complicações , Pessoa de Meia-Idade , Doenças Raras/diagnóstico , Falha de Tratamento , Resultado do Tratamento , Ácido Zoledrônico
6.
Internist (Berl) ; 57(6): 604-9, 2016 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-27055655

RESUMO

We report the case of a 74 year old man with a brain stem infarction, temporal headache and elevated inflammatory parameters. Giant cell arteritis with involvement of the temporal and vertebral arteries was proven by histology, duplex sonography and MRI. Although intensive immunosuppressive therapy was started, the patient developed two brain infarcts within 6 months. Initially, C­reactive protein and erythrocyte sedimentation rate were significantly elevated, but normalized over time. Involvement of the vertebral artery in giant cell arteritis is thought to be rare; steroid refractory courses are very rare. Brain stem infarction might be the consequence.


Assuntos
Infartos do Tronco Encefálico/diagnóstico , Infartos do Tronco Encefálico/etiologia , Encefalite/diagnóstico , Arterite de Células Gigantes/diagnóstico , Transtornos da Cefaleia/diagnóstico , Transtornos da Cefaleia/etiologia , Idoso , Anti-Inflamatórios/uso terapêutico , Infartos do Tronco Encefálico/prevenção & controle , Diagnóstico Diferencial , Encefalite/etiologia , Encefalite/prevenção & controle , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/tratamento farmacológico , Transtornos da Cefaleia/prevenção & controle , Humanos , Masculino , Prednisolona/uso terapêutico , Falha de Tratamento
7.
Z Rheumatol ; 74(4): 359-62, 2015 May.
Artigo em Alemão | MEDLINE | ID: mdl-25691108

RESUMO

CASE REPORT: We report the case of a patient with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with involvement of the temporal artery, presenting with clinical manifestations of giant cell arteritis and temporal arteritis, such as temporal headache, jaw claudication, weight loss, night sweats and increased inflammatory parameters. The ultrasound scan showed a typical halo sign of the temporal artery. DIAGNOSTICS: In the case of further atypical organ symptoms, e.g. hematuria and proteinuria, detailed differential diagnostic investigations are essential to clarify the situation. Histological findings from the affected organs play a decisive role. CONCLUSION: An involvement of the temporal artery due to ANCA-associated vasculitis is extremely rare and may mimic giant cell arteritis. The exact diagnosis of ANCA-associated vasculitis is, however, important because this leads to a different approach concerning therapy and prognosis.


Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico , Cefaleia Histamínica/etiologia , Febre de Causa Desconhecida/etiologia , Claudicação Intermitente/etiologia , Doenças Maxilomandibulares/etiologia , Cefaleia Histamínica/diagnóstico , Diagnóstico Diferencial , Febre de Causa Desconhecida/diagnóstico , Humanos , Claudicação Intermitente/diagnóstico , Doenças Maxilomandibulares/diagnóstico , Masculino , Pessoa de Meia-Idade
8.
Internist (Berl) ; 55(4): 443-7, 2014 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-24633430

RESUMO

We report the case of a patient with amyloid light-chain (AL) amyloidosis, presenting for more than 1.5 years with oligoarthritis as the only clinical symptom of the underlying disease. Developing further organ symptoms (heart and gastrointestinal tract) led to the definitive diagnosis. Joint involvement due to AL amyloidosis is extremely rare and may mimic rheumatoid arthritis. Arthritis might be the first symptom of the AL amyloidosis. The combination of arthritis and other organ disorders (e.g., proteinuria, heart failure, or diarrhea) should initiate further diagnostic efforts considering AL amyloidosis as a differential diagnosis. The diagnosis will be confirmed by the typical histology of synovia or involved organs including immunohistochemistry for typing amyloid and performing immunoelectrophoresis.


Assuntos
Amiloide/sangue , Amiloidose/diagnóstico , Artrite Reumatoide/diagnóstico , Artrite/diagnóstico , Articulação do Joelho , Mieloma Múltiplo/diagnóstico , Espondilartrite/diagnóstico , Sinovite/diagnóstico , Amiloidose/patologia , Artrite/patologia , Artrite Reumatoide/patologia , Biópsia , Medula Óssea/patologia , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/patologia , Diagnóstico Diferencial , Humanos , Mucosa Intestinal/patologia , Articulação do Joelho/patologia , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/patologia , Espondilartrite/patologia , Sinovite/patologia
9.
Dtsch Med Wochenschr ; 134(27): 1399-404, 2009 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-19551604

RESUMO

BACKGROUND AND OBJECTIVE: In the last few years public interest in the care of severely ill and dying patients has been growing. The aim of palliative medicine is to improve the care of the dying. However, this is still not achieved in many general hospitals. The Liverpool Care Pathway (LCP) for the care of the dying intends to change this situation. The aim of this study was to explore the views of professionals using the LCP as a framework for ensuring good care of the dying. METHODS: A qualitative study was conducted with an interdisciplinary focus group of ten professionals (nurses, physicians, spiritual adviser, social worker, physiotherapist and art therapist) to explore their views and experience after implementation of the LCP in a palliative care unit (PCU). The recorded discussion between them was transcribed verbatim and analysed using content analysis by three independent reviewers. RESULTS: Seven nurses and three physicians with an average work experience of 16 years each took part in the focus group. Based on the experience of 24 patients, the LCP was evaluated as very positive by all participants. In particular, three aspects were emphasized as having high relevance for a good quality of care: improvement of self-confidence, better control of symptoms, and enhancement of the communication between professionals and with patients and their relatives. However, some weaknesses were also mentioned, e.g. inadequate effort of documenting the beginning of implementing the scheme. CONCLUSION: The LCP was well received by professionals after the initial implementation of the LCP in a German PCU. The LCP was judged as an appropriate and helpful framework in the care of the dying.


Assuntos
Hospitais Gerais/normas , Cuidados Paliativos/métodos , Assistência Terminal/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Comunicação , Feminino , Grupos Focais , Alemanha , Humanos , Comunicação Interdisciplinar , Masculino , Pessoa de Meia-Idade , Cuidados Paliativos/organização & administração , Cuidados Paliativos/normas , Equipe de Assistência ao Paciente , Relações Profissional-Paciente , Assistência Terminal/organização & administração , Assistência Terminal/normas , Adulto Jovem
10.
Z Rheumatol ; 65(6): 520, 522-6, 2006 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-16550322

RESUMO

Takayasu's arteritis is a systemic disease, presenting as chronic inflammation of the main arteries. It usually affects the aorta and its large branches. General symptoms often include fatigue, subfebrile temperatures and weight loss. Complaints due to perfusion disorders are, for example, muscle pain, dizziness or claudication. Takayasu's arteritis is a rare disease which generally occurs in female patients under 40 years of age. We report on a patient with primary involvement of the mesenteric arteries. The disease process was fulminant and refractory to all therapeutic strategies. According to our knowledge this is the first case report from Germany of Takayasu's arteritis with mesenteric infarction.


Assuntos
Artéria Mesentérica Superior , Oclusão Vascular Mesentérica/diagnóstico , Arterite de Takayasu/diagnóstico , Angiografia , Aorta Abdominal/patologia , Aortite/diagnóstico , Aortite/tratamento farmacológico , Aortografia , Arteriopatias Oclusivas/diagnóstico , Arteriopatias Oclusivas/tratamento farmacológico , Artéria Celíaca/patologia , Colectomia , Colo/irrigação sanguínea , Colo/cirurgia , Terapia Combinada , Ciclofosfamida/uso terapêutico , Progressão da Doença , Quimioterapia Combinada , Etanercepte , Evolução Fatal , Feminino , Humanos , Imunoglobulina G/uso terapêutico , Isquemia/cirurgia , Jejuno/irrigação sanguínea , Jejuno/cirurgia , Oclusão Vascular Mesentérica/tratamento farmacológico , Oclusão Vascular Mesentérica/cirurgia , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Prednisolona/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Arterite de Takayasu/tratamento farmacológico , Arterite de Takayasu/cirurgia , Tomografia Computadorizada por Raios X , Ultrassonografia Doppler
11.
Dtsch Med Wochenschr ; 130(33): 1866-70, 2005 Aug 19.
Artigo em Alemão | MEDLINE | ID: mdl-16118728

RESUMO

BACKGROUND AND OBJECTIVE: The involvement of the cervical spine in rheumatoid arthritis can be essential regarding prognosis and mortality. The cervical myelopathy due to pannus formation and/or subluxation can be fatal. Aim of this study was to demonstrate the possible changes seen by MRI, and to establish a risk-profile for the individual patient. PATIENTS AND METHOD: Within a period of 24 months 214 patients with active RA were included. Clinical and laboratory data were obtained and plain radiographs of the cervical spine were taken. In patients with pathological findings on X-ray an MRI was performed (36 patients). RESULTS: Within the group of 214 patients 36 were identified to get an cervical spine MRI. In all cases the MRI showed significant changes: in 7 (19.5 %) pannus surrounded the dens, with additional erosions in one patient (2.7 %). In 25 (69.5 %) atlanto-axial-subluxation was present, 7 (19.5 %) showed a spondylodiscitis below C2. In 10 (27.8 %) a cervical myelopathy due to pannus or subluxation was present. There was no correlation of the MRI-results with symptoms and findings by examination. The patients with cervical spine disease were in all stages of RA. The majority was rheumatoid-factor positive. 5 out of 10 patients with cervical myelopathy showed neurological deficits: 3 patients died in consequence of neural compression, 2 patients underwent surgery successfully. CONCLUSION: The early detection of a cervical spine involvement in RA is essential to avoid possibly fatal complications. The only reliable method to achieve this goal has to include radiographic diagnostic including MRI of the cervical spine. Only this approach can answer the question of the right time-point for surgery. In daily clinical practice the cervical-spine involvement in RA is still underestimated.


Assuntos
Artrite Reumatoide/patologia , Vértebras Cervicais/patologia , Espondilartrite/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Artrite Reumatoide/mortalidade , Vértebras Cervicais/diagnóstico por imagem , Vértebras Cervicais/cirurgia , Discite/patologia , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Prognóstico , Radiografia , Fator Reumatoide/sangue , Fatores de Risco , Compressão da Medula Espinal/etiologia , Compressão da Medula Espinal/mortalidade , Doenças da Medula Espinal/patologia , Espondilartrite/mortalidade
12.
Virchows Arch ; 439(5): 675-82, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11764389

RESUMO

Collagen type IV is a structural matrix protein which contributes to the structural organization of the synovia. In order to characterize the distribution of this protein in synovia with chronic synovitis, collagen type IV was detected by immunochemistry in normal synovia and in synovia from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). A decrease of collagen type IV was observed in synovial layers of rheumatoid synovia, which statistically correlated with the grade of inflammation and with the thickness of the synovial layer. In vitro, we found no differences in the gene expression of collagen type IV in cultures of fibroblast-like synoviocytes (FLS) derived from OA and RA using a reverse-transcriptase polymerase chain reaction. Nevertheless, we observed a downregulating effect of tumor necrosis factor-alpha and interleukin (IL)-1beta on the gene expression of collagen type IV only in FLS isolated from patients with RA. The effect of IL-1beta was dose dependent. In summary, we observed an inflammation-associated decrease of collagen type IV in the synovial layer of rheumatoid synovia. Inflammatory cytokines may play a role in regulating the synthesis of collagen type IV in the rheumatoid process in vivo.


Assuntos
Artrite Reumatoide/metabolismo , Colágeno Tipo IV/biossíntese , Membrana Sinovial/metabolismo , Artrite Reumatoide/patologia , Células Cultivadas , Colágeno Tipo IV/genética , Relação Dose-Resposta a Droga , Regulação para Baixo , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Fibroblastos/patologia , Expressão Gênica/efeitos dos fármacos , Humanos , Interleucina-1/farmacologia , Sondas de Oligonucleotídeos/química , Osteoartrite do Quadril/metabolismo , Osteoartrite do Quadril/patologia , Osteoartrite do Joelho/metabolismo , Osteoartrite do Joelho/patologia , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Membrana Sinovial/efeitos dos fármacos , Membrana Sinovial/patologia , Fator de Necrose Tumoral alfa/farmacologia
13.
Z Rheumatol ; 59(5): 330-3, 2000 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-11116804

RESUMO

Case-reports from two female patients with an occlusion||| of the right external iliac artery and femoral artery are presented due to a||| large-vessel vasculitis. Both patients suffered from systemic lupus||| erythematosus This rare manifestation occurred within the first few years of||| the disease and was important for prognosis and further treatment. Other||| manifestations of the disease were general symptoms and polyarthritis. In one||| case the vasculitis was confirmed by histology. A fibrous thickening of the||| intima and a vasculitis of small vessels within the adventitia were the||| prominent feature. This observation supports the idea of small vessel||| vasculitis as the characteristic manifestation in lupus||| erythematosus.

14.
Z Rheumatol ; 59(3): 183-90, 2000 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-10929447

RESUMO

Primary systemic vasculitities play an important role in the differential diagnosis of systemic diseases. They can be classified according to newly developed classification criteria. In the past, systemic vasculitities were more diagnosed in the general phase of the disease. In the meantime limited forms can be diagnosed more easily. Prior to immunosuppressive therapy, a standardized staging-procedure is essential to define the extent of the disease. Therefore a program was established using methods that are easy to apply in all patients. In this setting the usefulness of this approach was investigated. Apart from the laboratory tests including antibody testing, the chest x-ray, consultation of the ENT specialist, ultrasound of the abdomen, and ECG were also very useful. The eye and neurological investigations, and the MRI of the head were of minor significance, but also important.


Assuntos
Vasculite/classificação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Quimioterapia Combinada , Feminino , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Equipe de Assistência ao Paciente , Valor Preditivo dos Testes , Vasculite/diagnóstico , Vasculite/tratamento farmacológico
15.
Z Rheumatol ; 59(5): 330-3, 2000 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-11142928

RESUMO

Case-reports from two female patients with an occlusion of the right external iliac artery and femoral artery are presented due to a large-vessel vasculitis. Both patients suffered from systemic lupus erythematosus This rare manifestation occurred within the first few years of the disease and was important for prognosis and further treatment. Other manifestations of the disease were general symptoms and polyarthritis. In one case the vasculitis was confirmed by histology. A fibrous thickening of the intima and a vasculitis of small vessels within the adventitia were the prominent feature. This observation supports the idea of small vessel vasculitis as the characteristic manifestation in lupus erythematosus.


Assuntos
Arteriopatias Oclusivas/diagnóstico , Arterite/diagnóstico , Artéria Femoral/patologia , Artéria Ilíaca , Lúpus Eritematoso Sistêmico/diagnóstico , Adulto , Angiografia , Arteriopatias Oclusivas/patologia , Arterite/patologia , Diagnóstico Diferencial , Feminino , Humanos , Artéria Ilíaca/patologia , Lúpus Eritematoso Sistêmico/patologia , Pessoa de Meia-Idade
16.
Z Arztl Fortbild Qualitatssich ; 93(2): 93-100, 1999 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-10355057

RESUMO

Autoimmune diseases play an increasing role in daily practise. Advanced understanding of the pathogenesis and pathophysiology enables an outcome orientated therapy leading to a far better prognosis. Immunosuppressive drugs are essential for the treatment. The therapeutical concepts are adopted to the individual character and stage of the disease. In the meantime, therapeutical regimes combine certain drugs. Although it is not possible to cure these autoimmune diseases, a remission can be achieved in most cases. Further developments will concentrate on more selective strategies and the potentials of gene therapy.


Assuntos
Doenças Autoimunes/tratamento farmacológico , Imunossupressores/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Vasculite/tratamento farmacológico
17.
Z Rheumatol ; 58(6): 333-44, 1999 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-10663939

RESUMO

The original structure of the synovial membrane is completely destroyed in the rheumatoid synovium and is characterized by mononuclear cell infiltration, synoviocyte proliferation, neo-vascularization, and deposition of extracellular matrix proteins. Adhesion molecules play an important role in the development of these pathologic changes. In this review we discuss the role of the adhesion receptors of the selectin, integrin and immunoglobulin families and of the CD44 molecule in the cell-cell and cell-matrix interaction in the pathogenesis of the inflammatory changes in rheumatoid arthritis.


Assuntos
Artrite Reumatoide/fisiopatologia , Comunicação Celular/fisiologia , Matriz Extracelular/fisiologia , Membrana Sinovial/fisiopatologia , Moléculas de Adesão Celular/fisiologia , Proteínas da Matriz Extracelular/fisiologia , Humanos , Integrinas/fisiologia
18.
Ann Rheum Dis ; 57(9): 559-65, 1998 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9849316

RESUMO

OBJECTIVE: To investigate in situ the expression of the integrin receptor subunits alpha 6 and beta 1 and the distribution of the ligand laminin in the synovia from osteoarthritis (OA) and rheumatoid arthritis (RA) patients and to study the effect of cytokines and antirheumatic drugs on the expression of the alpha 6 and beta 1 integrin subunits on long term cultures of fibroblast-like synoviocytes (FBS) derived from OA and RA. METHODS: The expression of the alpha 6 and beta 1 integrin subunits and the distribution of laminin were examined immunohistochemically in normal synovia and in synovia from patients with OA and RA. The effect of proinflammatory cytokines (IL1 beta and TNF alpha), and of antirheumatic drugs (salicylic acid, dexamethasone, and methotrexate) on the alpha 6 and beta 1 expression of cultured normal FBS and FBS from patients with OA and RA was determined by flow cytometry. RESULTS: In normal synovia and in OA synovia samples with a low grade of inflammation, synovial lining cells (SLC) showed a parallel expression and distribution of alpha 6 and laminin. In synovia samples of OA with a higher grade of inflammation and in the majority of RA synovia samples laminin was pericellularly distributed in a low number of SLC, whereas alpha 6 was expressed on the surface of a high number of SLC. In RA synovia samples with severe inflammatory changes the gradual loss of laminin generally corresponded to a decrease of the alpha 6 integrin subunit. beta 1 was always strongly expressed in all synovia samples detected. Proinflammatory cytokines up regulated the expression of alpha 6 and beta 1 on OA-FBS, whereas these effectors decreases alpha 6 and beta 1 on RA-FBS. In contrast, antirheumatic drugs, in particular methotrexate and dexamethasone, reduced the expression of alpha 6 and beta 1 on OA-FBS, whereas the same treatment on RA-FBS stimulated the expression of these integrin subunits. CONCLUSION: The gradual loss of laminin in chronic synovitis may contribute to the altered expression of alpha 6 in SLC. IL1 beta and TNF alpha down regulated the expression of the alpha 6 and beta 1 integrin subunits on long term cultures of FBS derived from RA. Therefore, these cytokines may be among the effectors regulating the expression of the alpha 6 integrin subunit in SLC in vivo. As antirheumatic drugs increase the expression of alpha 6 on RA-FBS, the presence of the laminin receptor may confer a protective effect on the synovia in vivo.


Assuntos
Antígenos CD/metabolismo , Artrite Reumatoide/metabolismo , Integrinas/metabolismo , Laminina/metabolismo , Membrana Sinovial/metabolismo , Antígenos CD/efeitos dos fármacos , Antirreumáticos/farmacologia , Artrite Reumatoide/patologia , Técnicas de Cultura de Células , Citocinas/farmacologia , Regulação para Baixo , Humanos , Técnicas Imunoenzimáticas , Integrina alfa6 , Integrina beta1/efeitos dos fármacos , Integrina beta1/metabolismo , Integrinas/efeitos dos fármacos , Osteoartrite/metabolismo , Osteoartrite/patologia
20.
Ann Rheum Dis ; 56(6): 382-5, 1997 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9227169

RESUMO

OBJECTIVES: Methotrexate (MTX) has been used in several autoimmune diseases. Apart from its use in rheumatoid arthritis, MTX has been assessed in small studies in patients with vasculitis, uveitis, and inflammatory bowel disease. The aim of this study was to evaluate the efficacy of MTX in a particular group of patients with systemic lupus erythematosus (SLE). PATIENTS: In an open prospective study 22 patients fulfilling the ACR criteria for SLE were included. Patients had one or more of the following manifestations; active non-destructive polyarthritis, dermatitis, vasculitis of the skin, pleuritis. All patients had been treated with corticosteroids for at least six months without achieving remission. Sixteen patients were taking antimalarial drugs in addition to corticosteroids, which were stopped at the beginning of the trial. Patients with renal and central nervous involvement were excluded from the study. All patients received MTX orally at a dose of 15 mg/week over six months. Corticosteroids were continued. As additional medication only indomethacin up to 100 mg/day was permitted if used before the start of the study. The outcome was evaluated using the SLE disease activity index (SLEDAI). RESULTS: Disease activity was evaluated after six months of MTX treatment. All patients completed the study period. The SLEDAI decreased significantly from mean (SD) 12.2 (3.99) to 4 (3.75) (p = 0.001). The prednisolone dose was reduced from a mean (SD) of 17.4 (12.8) at the beginning to 8.8 (5.36) mg/day at the end point of the study (p = 0.01). MTX was well tolerated. Four patients complained of general malaise. Two patients had transient increases in liver enzymes. In no case did MTX have to be stopped. CONCLUSIONS: In an open prospective study methotrexate was used in SLE patients with particular clinical characteristics. MTX was shown to be effective in reducing disease activity and sparing the dose of corticosteroids. Further controlled studies are necessary.


Assuntos
Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Metotrexato/uso terapêutico , Adulto , Idoso , Anticorpos Antinucleares/sangue , Sedimentação Sanguínea , Complemento C3c/metabolismo , Complemento C4/metabolismo , Esquema de Medicação , Quimioterapia Combinada , Glucocorticoides/administração & dosagem , Humanos , Lúpus Eritematoso Sistêmico/imunologia , Pessoa de Meia-Idade , Prednisolona/administração & dosagem , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...